Scotiabank analyst Sung Ji Nam maintained a Buy rating on Adaptive Biotechnologies (ADPT – Research Report) today and set a price target of $10.00. The company’s shares closed yesterday at $4.28.
According to TipRanks, Ji Nam is an analyst with an average return of -2.5% and a 48.40% success rate. Ji Nam covers the Healthcare sector, focusing on stocks such as Guardant Health, Olink Holding, and Pacific Biosciences.
Currently, the analyst consensus on Adaptive Biotechnologies is a Strong Buy with an average price target of $8.83, which is a 106.31% upside from current levels. In a report released on November 10, BTIG also reiterated a Buy rating on the stock with a $7.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
ADPT market cap is currently $592.1M and has a P/E ratio of -3.14.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Adaptive Biotechnologies (ADPT) Company Description:
Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. It harnesses the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson in September 2009 and is headquartered in Seattle, WA.
Read More on ADPT:
- Biotech Alert: Searches spiking for these stocks today
- Adaptive Biotechnologies price target lowered to $7 from $11 at BTIG
- Adaptive Biotechnologies price target lowered to $11 from $12 at JPMorgan
- Adaptive Biotechnologies sees 2023 MRD business revenue $100M-$105M
- Adaptive Biotechnologies reports Q3 EPS (35c), consensus (34c)
